This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Maxigesic 325 Acute Dental Pain Study

This study has been completed.
Information provided by (Responsible Party):
AFT Pharmaceuticals, Ltd. Identifier:
First received: August 16, 2011
Last updated: April 7, 2016
Last verified: January 2015
The purpose of this study is to determine whether the analgesic effects of Maxigesic USA are greater than acetaminophen, ibuprofen or placebo.

Condition Intervention Phase
Dental Pain Drug: Maxigesic 325 Drug: Acetaminophen Drug: Ibuprofen Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Maxigesic 325 Acute Dental Pain Study: A Double-blind, Placebo-controlled, Randomized, Parallel Group Comparison of the Effects of Maxigesic 325 Versus Acetaminophen, Ibuprofen and Placebo in Participants With Acute Dental Pain

Resource links provided by NLM:

Further study details as provided by AFT Pharmaceuticals, Ltd.:

Primary Outcome Measures:
  • SPID (Summed Pain Intensity Differences) [ Time Frame: 48 hours afte the first dose ]
    The time-adjusted SPIDs (Summed Pain Intensity Differences) of the VAS pain intensity scores up to 48 ours after the first dose of study medication.

Enrollment: 408
Study Start Date: April 2013
Study Completion Date: January 2015
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Maxigesic 325
Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
Drug: Maxigesic 325
Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
Other Name: Maxigesic
Active Comparator: Acetaminophen
Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
Drug: Acetaminophen
Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
Other Name: paracetamol
Active Comparator: Ibuprofen
Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
Drug: Ibuprofen
Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
Placebo Comparator: Placebo
Placebo tablets, every 6 hours, orally
Drug: Placebo
placebo, three tablets four times a day, with food for 48 hours

  Show Detailed Description


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provides written informed consent before initiation of any study-related procedures.
  • Males and females aged at least 10 years and not more than 60 years old on the day of consent.
  • Undergoing dental surgery for the extraction of at least 2 impacted third molar teeth.
  • A resting VAS pain intensity score at baseline (within 6 hours after the completion of surgery) of greater than or equal to 40 mm on a 100 mm VAS scale with 0 = no pain and 100 = worst pain imaginable.

Exclusion Criteria:

  • Has taken any NSAID or acetaminophen within 12 hours prior to the stat of surgery other than asprin less than or equal to 150 mg/day
  • Subjects who have received any anaesthetics within 24 hours prior to surgery
  • Hypersensitivity to opioids
  • Known to be pregnant or possibly pregnant
  • Women of childbearing potential who are unwilling to take adequate contraceptive precautions, i.e., hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence. A women of childbearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone a partial or total hysterectomy or surgical sterilization, e.g. bilateral tubal ligation, bilateral oophorectomy.
  • Women of childbearing potential who are unwilling to undergo an urine pregnancy test.
  • Suffering from a neurological disorder relating to pain perception or any acute or chronic condition that, in the opinion of the investigator, makes the subject unsuitable from an efficacy or safety perspective.
  • In the opinion of the investigator, unable to understand the visual analogue pain score or comply with the protocol requirements.
  • Currently, or in the last 30 days, has been in a clinical trial involving another study drug.
  • Currently treated with an ACE inhibitor, warfarin, steroid (other than nasal steroids or topical steroids with the approval of the investigator) cyclosporin, tacrolimus or methotrexate, or any other medication felt by the investigator to interfere with safety or efficacy evaluations.
  • Participant weight < 50 kg or > 120 kg.
  • Has a history of drug or alcohol abuse.
  • Suffering from any other disease or condition which, in the opinion of the investigator, means that it would not be in the participants best interests to participant in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01420653

United States, Texas
Premier Research
Austin, Texas, United States, 78705
New Zealand
Clinical Trial New Zealand
Hamilton, Waikato, New Zealand
Clinical Solutions Ltd.
Auckland, New Zealand, 0622
Southern Clinical Trials
Christchurch, New Zealand
Sponsors and Collaborators
AFT Pharmaceuticals, Ltd.
Principal Investigator: John Currie, Doctor Clinical Trial New Zealand
  More Information

Responsible Party: AFT Pharmaceuticals, Ltd. Identifier: NCT01420653     History of Changes
Other Study ID Numbers: AFT-MX-6
Study First Received: August 16, 2011
Last Updated: April 7, 2016

Additional relevant MeSH terms:
Tooth Diseases
Stomatognathic Diseases
Facial Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017